Transforming Growth Factor β1 (TGFβ1) and Vascular Endothelial Growth Factor (VEGF) in the blood of healthy people and patients with Graves’ orbitopathy — a new mechanism of glucocorticoids action? by Kajdaniuk, Dariusz et al.
348
Prace oryginalne/original PaPers
Endokrynologia Polska
DOI: 10.5603/EP.2014.0048
Tom/Volume 65; Numer/Number 5/2014
ISSN 0423–104X
Dariusz Kajdaniuk M.D., Ph.D., Department of Pathophysiology and Endocrinology, Medical University of Silesia, Pl. Traugutta 2,  
41–800 Zabrze, Poland, fax: +48 32 271 26 41, e-mail: patofizjozab@sum.edu.pl
Transforming Growth Factor b1 (TGFb1) and Vascular 
Endothelial Growth Factor (VEGF) in the blood of healthy 
people and patients with Graves’ orbitopathy  
— a new mechanism of glucocorticoids action?
Transformujący czynnik wzrostu b1 (TGFb1) i naczyniowo-śródbłonkowy czynnik 
wzrostu (VEGF) we krwi ludzi zdrowych i chorych z orbitopatią Gravesa  
— nowy mechanizm działania glikokortykosteroidów? 
Dariusz Kajdaniuk1*, Bogdan Marek1*, Danuta Niedziołka-Zielonka1, Wanda Foltyn1, Mariusz Nowak1, 
Lucyna Siemińska1, Halina Borgiel-Marek2, Joanna Głogowska-Szeląg1, Zofia Ostrowska3,  
Lucjan Drożdż5, Beata Kos-Kudła1 
*Both co-authors contributed to the manuscript equally and both should be considered as 1st co-author 
1Department of Pathophysiology and Endocrinology, Medical University of Silesia, Zabrze, Katowice, Poland 
2Department and Clinic of Maxillofacial Surgery, Medical University of Silesia, Katowice, Poland 
3Department of Biology, Medical University of Silesia, Katowice, Poland  
4Outpatients’ Clinic, Town’s Hospital No 4, Gliwice, Poland
Abstract
Introduction: The first part of this paper is related to healthy people and presents concentrations of TGFb1 and VEGF in blood (with and 
without dividing data with respect to sex), their single measurement values (at 8am), Mean Daily Concentrations (MDC), Area Under the 
Curves (AUC; total daily secretion), and circadian rhythm. The second part of the work is related to Graves’ orbitopathy (GO). The aim 
of the study were: 1) to determine the physiological pattern of TGFb1 and VEGF secretion; 2) to compare the serum TGFb1 and VEGF 
circadian profile in newly diagnosed thyreotoxic patients with active GO and healthy controls (H); and 3) to estimate the influence of 
high-dose intravenous methylprednisolone pulse therapy (MP) on TGFb1 and VEGF blood levels in GO. 
Material and methods: Twenty-two healthy (H) subjects and 16 hyperthyroid GO patients were treated with MP (6 g/14 days) and fol-
lowed up by ophthalmological assessment. Blood was collected before and after 2 weeks MP-therapy. TGFb1 and VEGF levels were 
determined by the ELISA method.
Results: No difference was observed in the concentrations of TGFb1 and VEGF in the blood of healthy women and men — in further 
analysis, a combined healthy male and female cohort was used (H). While the absence of circadian rhythms in the concentrations of TGFb1 
and VEGF allows the application of a single measurement approach, MDC and AUC measurements were found to be more precise. There 
were no differences in TGFb1 MDC/AUC between GO and H. VEGF MDC/AUC in GO were higher than in H. MP-therapy increased 
TGFb1 MDC/AUC, thus in GO after MP, the TGFb1 MDC/AUC were higher than in H. There were no differences in VEGF MDC/AUC 
during MP-therapy. MP-therapy was effective in 15/16 patients. 
Conclusions: 
1. MP-therapy increases MDC and AUC of TGFb1. The effectiveness of MP-therapy in patients with active GO may be related to its influ-
ence on TGFb1 concentrations in blood. The results suggest the existence of a new mechanism of glucocorticoids action, consisting of an 
increase in the secretion of TGFb1. 
2. The elevated serum VEGF in thyreotoxic patients with active GO may reflect long-standing autoimmune processes in orbital and thyroid 
tissues and intensified angiogenesis in the thyroid gland. (Endokrynol Pol 2014; 65 (5): 348–356)
Key words: TGFbeta1; VEGF; transforming growth factor beta 1; vascular-endothelial growth factor; healthy; thyroid; Graves; orbitopathy; 
fibrosis; angiogenesis; methylprednisolone; glucocorticoids
Streszczenie
Wstęp: Pierwsza część pracy dotyczy ludzi zdrowych — dostarcza dane o stężeniach TGFb1 i VEGF we krwi (z podziałem i bez podziału 
na płeć), ich wartości punktowe (godz. 8), średniodobowe stężenie (MDC), pole pod krzywą (AUC; całkowite dobowe wydzielanie), rytm 
okołodobowy. Druga część pracy dotyczy orbitopatii Gravesa (GO). Celem pracy było: 1) określenie fizjologicznego wzoru wydzielania 
TGFb1 i VEGF; 2) porównanie okołodobowych surowiczych stężeń TGFb1 i VEGF u chorych z nowo rozpoznaną nadczynnością tarczycy 
i aktywną fazą GO oraz u ludzi zdrowych (H); 3) ocena wpływu wysokodawkowej dożylnej pulsacyjnej terapii metyloprednizolonem 
(MP) na stężenia TGFb1 i VEGF we krwi chorych z GO. 
Materiał i metody: Przebadano 22 zdrowych (H); 16 pacjentów z nadczynnością tarczycy i GO leczonych MP (6 g/14 dni) obserwowanych 
okulistycznie. Krew pobierano przed i po 2 tygodniach terapii MP. Stężenia TGFb1 i VEGF oznaczono metodą ELISA. 
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Introduction
TGFb1 is a multifunctional cytokine. Organ and tissue 
distinctiveness hinder the unambiguous characterisa-
tion of the cytokine. However, there are constant func-
tions of TGFb1 inducing no controversy: it participates 
in the control of cell growth and differentiation, induces 
fibrosis and scar formation (the process of ‘wound 
healing’), causes the suppression of immune response, 
and is involved in angiogenesis, the development of 
tumours, and inflammatory processes. Thus, there are 
three fundamental directions of its activities: I. TGFb1 
regulates cell proliferation, growth, differentiation and 
cells movement; II. It has immunomodulatory effects; 
III. It has profibrogenic effects [1–5]. TGFb1 is involved 
in the suppression of the immune response. It inhibits 
the proliferation, differentiation and activity of cells 
involved in humoral and cellular responses, reduces 
the expression of MHC molecules, the cellular toxicity, 
the production of antibodies, and inhibits the secretion 
of cytokines [2, 3, 5–7]. On the surface of B cells are 
located receptors for TGFb1 — their stimulation leads 
to the inhibition of B cell proliferation [8–10]. TGFb1 
inhibits T cell proliferation [10] in response to polyclonal 
mitogens [11]. On the other hand, in the inflamed tis-
sues, an increase of activation of T helper cells CD4+ 
which produce TGFb1 is seen [9, 12]. This cytokine 
inhibits macrophages’ maturation and activity [6, 10, 
11]. The immunosuppressive and anti-inflammatory 
effects of TGFb1 [3] have been confirmed in vitro [1, 6, 
13] and in vivo [1, 13]. Mouse model studies have dem-
onstrated that TGFb1 is involved in the pathogenesis 
of autoimmune diseases — systemic administration 
of TGFb1 suppresses autoimmune disease while the 
anti-TGFb1 antibodies cause its progression. It has been 
demonstrated that mutations in the TGFb1 gene result 
in the development of a phenotype with characteristics 
Wyniki: Nie stwierdzono różnic w stężeniu TGFb1 i VEGF we krwi między zdrowymi kobietami i zdrowymi mężczyznami — dalszym 
analizom poddawano więc grupę zdrowych (H) składającą się z kobiet i mężczyzn. Krew pobierano przed i po 2 tygodniach terapii MP. 
Choć wykazanie braku rytmów okołodobowych stężeń TGFb1 i VEGF we krwi umożliwia zastosowanie ich oceny punktowej to jednak 
stwierdzono, że bardziej precyzyjną jest ocena MDC i AUC. Nie wykazano różnicy w TGFb1 MDC/AUC między GO i H. VEGF MDC/
AUC były wyższe u GO niż u H. MP zwiększył TGFb1 MDC/AUC, tym samym u GO po MP, TGFb1 MDC/AUC były też wyższe niż u H. 
Nie stwierdzono różnicy w VEGF MDC/AUC podczas MP. MP był skuteczny u 15/16 chorych. 
Wnioski: 
1. Terapia MP zwiększa MDC i AUC TGFb1. Skuteczność MP u chorych z aktywną fazą GO może być związana z jego wpływem na 
stężenia TGFb1 we krwi, co sugeruje istnienie nieznanego dotąd mechanizmu działania glikokortykosteroidów polegającego na zwięk-
szaniu wydzielania TGFb1. 
2. Podwyższone stężenia VEGF we krwi u chorych z nadczynnością tarczycy i aktywną fazą GO mogą być odzwierciedleniem dłu-
gotrwałego procesu autoimmunologicznego w tkankach oczodołu i tarczycy oraz nasilonej angiogenezy w gruczole tarczowym. 
(Endokrynol Pol 2014; 65 (5): 349–356)
Słowa kluczowe: TGFbeta1; VEGF; transformujący czynnik wzrostu beta 1; naczyniowo-śródbłonkowy czynnik wzrostu; zdrowi; tarczyca; 
Graves; orbitopatia; włóknienie; angiogeneza; metyloprednizolon; glikokortykosteroidy
This work was supported by the State Committee for Scientific Research (KBN, Poland) grants nr 3P05B05322 and 3P05B03123 and Medical 
University of Silesia grants nr NN 1-028/05 and 2-197/05, 5-154/04.
typical of autoimmune diseases [5, 14]. Furthermore, 
the relationship between TGFb1 and fibrosis of vari-
ous tissues and organs is increasingly being described. 
Although TGFb1 plays a critical role in tissue repair, 
overproduction of the cytokine can lead to an excessive, 
uncontrolled deposition of fibrous tissue [5, 15]. 
Angiogenesis is an important component of many 
physiological and pathological processes [16–27]. Dis-
ease processes which have been shown to increase 
vascularity include, in particular, endocrine glands ill-
ness [24, 25], acromegaly [19], pituitary adenomas [26, 
27], autoimmune thyroid disease, goitre, neoplasms 
[18, 22] and eye disorders — retinopathy occurring in 
premature infants [18, 28], diabetic retinopathy [18, 
20, 21, 29–31], uveitis and other ocular illnesses. An-
giogenesis commonly occurs in inflammatory diseases 
[18–20, 22, 24–27]. Activators of angiogenesis include 
VEGF (induces vascular permeability, endothelial cells 
proliferation, migration and adhesion of leukocytes) 
and TGFb1 (promotes maturation of blood vessels, 
deposition of extracellular matrix components, induces 
endothelial cells proliferation, differentiation of mesen-
chymal cells to pericytes) [5, 24, 25]. VEGF is produced 
by the endothelial cells, fibroblasts and the majority of 
inflammatory cells (macrophages, lymphocytes, neu-
trophils and eosinophils) [24, 32]. Starting the process 
of angiogenesis is usually dependent on several factors. 
These include the immune/inflammatory response (e.g. 
immune/tissue infiltrating inflammatory cells) [18, 24] 
and hormonal changes (e.g. increased levels of IGF-I, 
TSH stimuli) and VEGF, which plays a role in all the 
situations in which angiogenesis occurs [24, 25, 33] 
Among the mechanical factors that trigger angiogenesis, 
an important role is played by increased blood flow in 
the capillary vascular (e.g. hyperthyroidism) [24]. 
The first part of this paper is related to healthy peo-
ple — it presents concentrations of TGFb1 and VEGF in 
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blood (with and without dividing the data with respect 
to sex), their single measurement values (at 8 am), Mean 
Daily Concentrations (MDC), Area Under the Curves 
(AUC; total daily secretion), and circadian rhythm.
The second part of this work is related to Graves’ 
orbitopathy (GO). There are two clinical phases of 
GO: active (oedematous-infiltrative orbitopathy) and 
non active (fibrosis). GO is thought to be an inflam-
matory disorder of autoimmune background. The 
thyroid-stimulating hormone (TSH) receptor (TSHR) 
is the autoantigen responsible for the hyperthyroid-
ism of Graves’ disease. Its role in the development of 
GO is unclear [34–38]. Expression of TSHR mRNA is 
augmented in orbital tissues from GO patients, and in 
newly differentiated adipocytes derived from precursor 
cells within the orbit. TGFb1 inhibits TSHR expression 
and adipogenesis by orbital fibroblasts in vitro, effects 
that would seem to favour disease remission [34, 39]. 
TGFb mRNA levels have also been found to be pres-
ent at higher levels in orbital tissue from GO patients 
compared to controls [40]. VEGF is produced by thyroid 
follicles in response to chronic activation of TSHR. 
VEGF stimulates its receptors on thyroid endothelial 
cells, leading to hypervascularity of the thyroid gland 
[24, 25]. It is possible that glucocorticoids modulate 
TGFb1 and VEGF production.
The objective of this study was to evaluate the role 
of selected growth factors related to the processes of 
fibrosis, immunosuppression and angiogenesis in the 
GO pathogenesis. The aims of the study were: 1) to 
determine the physiological pattern of TGFb1 and 
VEGF secretion (assessment of their concentrations in 
the blood of healthy people with and without strati-
fication with respect to sex, circadian rhythm, mean 
daily concentrations, and total daily secretion); 2) to 
compare the serum TGFb1 and VEGF circadian profile 
in newly diagnosed thyreotoxic patients with active GO 
and healthy controls; and 3) to estimate the influence 
of high-dose intravenous methylprednisolone pulse 
therapy on TGFb1 and VEGF blood levels in patients 
with active GO and to assess their potential as a guide 
to immunosuppresive therapy.
Material and methods
The fundamental part of this study was conducted 
in 38 individuals: 16 newly diagnosed thyreotoxic 
patients with active Graves’ orbitopathy (oedematous-
infiltrative phase of the disease) (group GO) (12 women, 
4 men; mean age 37 ± 9 years) were treated with high-
dose intravenous methylprednisolone pulse therapy 
(MP) (6 g/14 days — 1 g per day repeated within two 
weeks) (groups: GO before MP vs. GO after MP) and 
followed up by an ophthalmological assessment (two 
and four weeks after the beginning of MP therapy); the 
control group (group H) consisted of 22 healthy volun-
teers age- and sex-matched to group GO. The research 
was approved by the Ethical Committee of the Medical 
University of Silesia, and was carried out in 2002–2007. 
In all those examined, the current endocrinological sta-
tus was defined on the basis of thyroid gland ultrasound, 
blood levels of TSH, fT4 (eventually +fT3), thyrotropin 
receptor antibodies (TRAb), and anti-thyroid peroxidase 
antibodies (TPOAb). An ophthalmological assessment re-
lating to the status of cornea, extraocular muscles, eyelids, 
proptosis and optic nerve function was carried out during 
the study. This provided a measurement of visual acuity, 
intraocular pressure, proptosis, fundoscopy, the assess-
ment of ocular motility, visual fields, colour vision, lagoph-
thalmos and corneal changes. To evaluate eye disease, a 
clinical activity score (CAS) and an ophthalmopathy index 
(OI) were used. The active phase of GO was confirmed 
before MP treatment with magnetic resonance imaging 
(MRI) of the orbits. 
In GO and H groups, blood was collected at four 
points during the day (at 7 am, 1 pm, 7 pm, and 
1 am) to determine the presence of a possible circadian 
rhythm of TGFb1 and VEGF, the calculation of their 
Mean Daily Concentrations (MDC) in blood and total 
daily secretion (Area Under the Curves; AUC) to blood. 
In a similar manner, blood was collected two weeks 
after MP therapy. Whole blood and serum and plasma 
derived from its parts were stored at –80°C until test-
ing. The creation of a control group of healthy people 
(H) composed of men and women (for estimation of 
MDC/AUC) was preceded by a comparative analysis of 
the concentrations of TGFb1 and VEGF in the blood of 
women (n = 31) and the concentrations of TGFb1 and 
VEGF in the blood of men (n = 28). For the purposes 
of this analysis, blood was taken once at 8 am. 
Serum levels of TGFb1 and VEGF were measured 
by an enzyme-linked immunosorbent assay (ELISA) 
method using Quantikine Immunoassay, (R&D Sys-
tems, USA) kits. Tests were performed in the Depart-
ment of Pathophysiology and Endocrinology with a 
Universal Microplate Spectrophotometer – m QUANT 
(BIOTEK INC). The sensitivity of the method was: for 
TGFb1 — < 7 pg/mL, and for VEGF — < 5 pg/mL. Intra-
assay error and inter-assay error were respectively: 
for TGFb1 — 4.9% to 10.3%, and for VEGF — 5.1% to 
6.2%. TRAb and TPOAb were estimated, respectively, 
by a radioimmune assay (RIA) method and the ELISA 
method. Serum levels of TSH and free thyroid hor-
mones were assayed immunoenzymatically (MEIA), 
by routine laboratory techniques.
For each quantitive parameter, basic statistical character-
istics were made — mean, SD (standard deviation), SEM 
(standard error of the mean), minimal and maximal 
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value, median, quartiles 25% and 75%, 95% confidence 
interval. In the statistical analysis, p < 0.05 was regarded 
as statistically significant. Shapiro-Wilk test performed 
for evaluation of normal distribution of parameter. 
Homogeneity of variance was checked by Fischer test. 
Student’s t-test was used for comparison of unpaired 
groups of parameters that follow normal distribution. 
Pre-treatment and post-treatment data within the same 
group were compared with Student’s paired t-test. For 
the assessment of intergroup correlations, a Spearman 
Rank Correlation test was used. Chronobiological pa-
rameter estimation was performed using the cosinor 
method [Model: M+A*cos((Pi/12)*T+fi)]. 
Results
The first part of this paper is related to healthy people. 
Table I (a, b, c) shows the concentrations of TGFb1 and 
VEGF in the blood of healthy people. These Tables (Ia, 
Ib, Ic) illustrate the way how we finally formed a control 
group of healthy people (H) who took part in the sec-
ond, fundamental, part of the experiment concerning 
Graves’ orbitopathy. No difference was observed in 
the concentrations of TGFb1 and VEGF in the blood of 
healthy women and healthy men (single measurement 
at 8 am) (Table Ia) (Table Ib presents the same material 
without stratification with respect to sex). In view of 
this, it was concluded that in further analysis we could 
use a combined male and female cohort. Despite the 
fact that the absence of circadian rhythms in the con-
centrations of TGFb1 and VEGF (Table III) allowed for 
an application of a single measurement approach, we 
found it was more precise to evaluate the Mean Daily 
Concentrations (MDC) and Area Under the Curves 
(AUC) of the TGFb1 and VEGF. So we finally formed 
a control group of healthy people (H) (Table Ic), of whom 
the MDC and AUC of TGFb1 and VEGF were then com-
pared to the study group (GO) (Table II, IV, V, VI).
There were no significant (NS) differences in mean 
daily serum concentrations (MDC) and area under 
the curve (AUC) of TGFb1 between patients with GO 
and healthy controls (H). In GO patients, the MDC of 
VEGF was significantly higher than in healthy people 
(H) and the AUC of VEGF was also significantly higher 
than in H (Table IV).
High-dose intravenous methylprednisolone pulse 
therapy (MP) significantly increased MDC and AUC 
of TGFb1 (TGFb1MDC and TGFb1AUC increased during 
MP therapy in 15/16 patients). In this way, in patients 
Table Ib. Concentrations of TGFb1 and VEGF in blood of healthy people (single measurement at 8 am)
Tabela Ib. Stężenia TGFb1 i VEGF we krwi ludzi zdrowych (oznaczenie punktowe o godz. 8)
Healthy ♀♂  
(n = 59)
Mean SD SEM Confidence 
interval 
–95%
Confidence 
interval 
+95%
Median Minimum Maximum Lower 
quartile
Upper 
quartile
TGFb1 [ng/mL] 39.83 11.4 1.48 36.86 42.8 37.68 16.24 67.1 33.47 44.92
VEGF [ng/mL] 258.59 197.93 25.77 207.01 310.17 172.32 37.38 987.87 116.3 371.31
Table Ic. Mean Daily Concentrations (MDC) and Area Under the Curves (AUC; total daily secretion) of TGFb1 and VEGF in 
blood of healthy people (group H)
Tabela Ic. Średnie dobowych stężeń (MDC) i całkowitego dobowego wydzielania (pól pod krzywą; AUC) dla TGFb1 i VEGF 
we krwi ludzi zdrowych (grupa H)
Healthy (gr. H) 
♀♂ (n = 22) 
Mean SD SEM Confidence 
interval  
–95%
Confidence 
interval  
+95%
Median Minimum Maximum Lower 
quartile
Upper 
quartile
TGFb1MDC [ng/mL] 34.57 6.66 1.42 31.61 37.52 32.98 25.21 46.34 29.13 42.14
TGFb1AUC 412.05 81.97 17.48 375.71 448.4 391.54 299.02 551.64 358.58 509.08
VEGFMDC [ng/mL] 236.11 106.68 22.74 188.81 283.41 224.44 61.78 415.11 150.81 326.87
VEGFAUC 2,824.76 1,292.3 275.52 2,251.78 3,397.73 2,643.68 725.06 4,904.72 1,821.82 3,922.92
Table Ia. Comparison of concentrations of TGFb1 and 
VEGF in blood of healthy women and healthy men (single 
measurement at 8 am)
Tabela Ia. Porównanie stężeń TGFb1 i VEGF we krwi 
zdrowych kobiet i zdrowych mężczyzn (oznaczenie punktowe 
o godz. 8)
♀ (n = 31) ♂ (n = 28) 
Mean ± SD Mean ± SD p
TGFb1 [ng/mL] 37.89 ± 10.48 41.98 ± 12.16 0.171
VEGF [ng/mL] 298.65 ± 179.85 214.24 ± 210.56 0.1023
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‘GO after MP’, the TGFb1MDC and TGFb1AUC were sig-
nificantly higher than in healthy people (H) (Table V). 
There were no differences in MDC and AUC of VEGF 
during MP therapy. Also in GO patients before MP, 
as in ‘GO after MP’, the VEGFMDC and VEGFAUC were 
significantly higher than in healthy people (H) (Table V, 
VI). The treatment was efficient – all patients showed 
a significant improvement in the signs and symptoms 
of orbital inflammation, and most patients showed an 
improvement in proptosis and diplopia. CAS fell within 
two weeks of MP therapy in 15 of 16 patients (before 
treatment: 5.7 ± 1.9 and after: 3.6 ± 0.9) and remained 
stable during the follow-up period. Post-treatment OI 
was improved (mean values 3.5 ± 1.3 vs. 2.6 ± 1.02). 
Proptosis was reduced (mean values 23.04 mm ± 1.54 
vs. 21.64 mm ± 1.6) in 15 of 16 patients. Visual acuity 
was improved in 15 of 16 patients. Ocular motility 
was normalised or improved in 15 of 16 patients. The 
clinical assessment of the effect of the glucocorticoids 
pulse therapy for Graves’ orbitopathy showed a good 
response in eight patients, a fair response in seven 
(responders), and no response in one (non-responder). 
No significant correlation was found between fT4, fT3 
and TGFb1, VEGF blood levels. We also did not find 
any correlation between measured growth factors and 
parameters of autoimmune thyroid disease such as 
TRAb or TPOAb. 
Discussion
GO is an autoimmune disease in which CD4+ and 
CD8+ T cells, B cells, plasma cells and macrophages 
infiltrate the orbital soft tissue/periorbital space lead-
ing to tissue remodelling. Enlargement of orbital tissue 
mass occurs through the accumulation of extracellular 
matrix (ECM), scar-forming myofibroblasts, and/or fat 
Table II. Mean Daily Concentrations (MDC) and Area Under the Curves (AUC; total daily secretion) of TGFb1 and VEGF in 
blood of patients with active Graves’ Orbitopathy (group GO)
Tabela II. Średnie dobowych stężeń (MDC) i całkowitego dobowego wydzielania (pól pod krzywą; AUC) dla TGFb1 i VEGF 
we krwi chorych z czynną orbitopatią Gravesa (grupa GO)
Graves’ 
Orbitopathy  
(gr. GO) ♀♀  
(n = 16) 
Mean SD SEM Confidence 
interval  
–95%
Confidence 
interval  
+95%
Median Minimum Maximum Lower 
quartile
Upper 
quartile
TGFb1MDC [ng/mL] 39.15 9.6 2.4 34.04 44.27 38.69 22.84 59.33 33.35 47.3
TGFb1AUC 471.12 114.89 28.72 409.9 532.34 465.65 277.62 708.5 401.7 568.8
VEGFMDC [ng/mL] 463.12 330.45 82.61 287.03 639.21 356.9 99.71 1,366.02 270.4 572.7
VEGFAUC 5,603.44 3,943.28 985.82 3,502.22 7,704.66 4,350.87 1,297.76 16,322.4 3,331.64 6,909.85
Table III. Assessment of circadian rhythm of TGFb1 and VEGF concentrations in blood of healthy people (group H) and patients 
with active Graves’ Orbitopathy (group GO)
Tabela III. Ocena rytmu dobowego stężeń TGFb1 i VEGF we krwi u ludzi zdrowych (grupa H) oraz pacjentów z czynną 
orbitopatią Gravesa (grupa GO)
Circadian rhythm (cosinor method) Healthy (gr. H) Graves’ Orbitopathy (gr. GO)
TGFb1 [ng/mL] No rhythm No rhythm
VEGF [ng/mL] No rhythm No rhythm
Table IV. Mean Daily Concentrations (MDC) and Area Under the Curves (AUC; total daily secretion) of TGFb1 and VEGF in 
blood of patients with active Graves’ Orbitopathy (GO) and in healthy controls (H)
Tabela IV. Porównanie średnich dobowych stężeń (MDC) i całkowitego dobowego wydzielania (pól pod krzywą; AUC) dla 
TGFb1 i VEGF we krwi chorych z aktywną oftalmopatią Gravesa (GO) i w grupie kontrolnej zdrowych (H)
Groups TGFb1 [ng/mL] 
MDC ± SD; ± SEM
TGFb1 
AUC ± SD; ± SEM
VEGF [ng/mL] 
MDC ± SD; ± SEM
VEGF 
AUC ± SD; ± SEM
GO 39.15 ± 9.6; ± 2.4 471.12 ± 114.89; ± 28.72 463.12 ± 330.45; ± 82.61 5,603.44 ± 3,943.28; ± 985.82
H 34.57 ± 6.66; ± 1.42 412.05 ± 81.97; ± 17.48 236.11 ± 106.68; ± 22.74 2,824.76 ± 1,292.3; ± 275.52
GO vs. H NS NS  < 0.05  < 0.05
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[41–45]. The earliest stages of GO involve the infiltration 
of the orbital tissue by T cells [41, 42]. T cell-fibroblast 
interactions are mediated through cytokines, adhesion 
molecules, and other co-stimulatory molecules [42, 46]. 
These interactions stimulate fibroblasts to deposit ECM 
[42, 47, 48] and/or differentiate into myofibroblasts or 
adipocytes [34, 42, 46, 49]. TGFb1 is synthesised primar-
ily by platelets, macrophages/monocytes, lymphocytes, 
fibroblasts, and epithelial cells [50]. TGFb1 is a potent 
stimulator of glycosaminoglycans accumulation by 
retroocular connective tissue. Stimulation of glycosami-
noglycans production by the cytokine, released from 
lymphocytes or macrophages infiltrating the retroocular 
space, may play a role in the accumulation of glycos-
aminoglycans in the retroocular and perimysial connec-
tive tissues in GO [47, 51]. TGFb increases hyaluronan 
(the major ECM glycosaminoglycan) secretion into the 
culture medium of orbital fibroblasts in vitro [40, 42, 
51]. TGFb1 is one of the key mediators of fibrogenesis. 
An increased TGFb1 expression has been observed in 
patients with pulmonary, kidney, and liver fibrosis. In 
chronic hepatitis, the prolonged stimulation of hepatic 
stellate cells, being the result of chronic damage to hepa-
tocytes, results in the release of profibrogenic abundant 
factors such as TGFb1 and leads to the development of 
liver cirrhosis [5]. On the other hand, TGFb1 inhibits 
TSHR expression and adipogenesis in the orbit that 
would seem to favour disease remission [34, 39]. Hu-
man recombinant TGFb1 was immunosuppressive in 
patients with Graves’ disease and in controls. In both 
groups, it inhibited the proliferation of peripheral blood 
mononuclear cells and of peripheral and thyroid de-
rived T cell lines and clones in response to non-specific 
stimuli. It also decreased the number of serine esterases 
expressing cytotoxic T cells and suppressed the recogni-
tion of thyroid epithelial cells by thyroid autoantigen 
specific T cell clones. TGFb1 may exert a variety of 
down-regulatory influences in Graves’ disease. It may 
be of importance for the suppression of autoaggression 
in persons predisposed to autoimmunity; it may be 
quantitatively overrun by immunostimulatory influ-
ences in the acute phase of the disease; and it may be 
Table V. Mean Daily Concentrations (MDC) and Area Under the Curves (AUC; total daily secretion) of TGFb1 in blood of 
patients with active Graves’ Orbitopathy (GO) treated with high-dose intravenous methylprednisolone pulse therapy (MP) 
(groups: GO before vs. GO after MP) and in healthy people (H)
Tabela V. Porównanie średnich dobowych stężeń (MDC) i całkowitego dobowego wydzielania (pól pod krzywą; AUC) dla 
TGFb1 we krwi chorych z aktywną orbitopatią Gravesa (GO) poddanych wysoko dawkowej pulsacyjnej dożylnej terapii 
metyloprednizolonem (MP) (grupy: GO przed/before MP, GO po/after MP) i u zdrowych (H)
Groups TGFb1 [ng/mL] 
MDC ± SD; ± SEM
TGFb1 
AUC ± SD; ± SEM
GO before MP 39.15 ± 9.6; ± 2.4 471.12 ± 114.89; ± 28.72
GO after MP 44.79 ± 9.41; ± 2.35 542.35 ± 111.73; ± 27.93
H 34.57 ± 6.66; ± 1.42 412.05 ± 81.97; ± 17.48
GO before MP vs. GO after MP p = 0.0003 p = 0.0002
GO before MP vs. H p = 0.0904 p = 0.0722
GO after MP vs. H p = 0.0004 p = 0.0002
Table VI. Mean Daily Concentrations (MDC) and Area Under the Curves (AUC; total daily secretion) of VEGF in blood of 
patients with active Graves’ Orbitopathy (GO) treated with high-dose intravenous methylprednisolone pulse therapy (MP) 
(groups: GO before MP vs. GO after MP) and in healthy people (H)
Tabela VI. Porównanie średnich dobowych stężeń (MDC) i całkowitego dobowego wydzielania (pól pod krzywą; AUC) dla 
VEGF we krwi u chorych z aktywną orbitopatią Gravesa (GO) poddanych wysoko dawkowej pulsacyjnej dożylnej terapii 
metyloprednizolonem (MP) (grupy: GO przed/before MP vs. GO po/after MP) i u zdrowych (H)
Groups VEGF [ng/mL] 
MDC ± SD; ± SEM
VEGF 
AUC ± SD; ± SEM
GO before MP 463.12 ± 330.45; ± 82.61 5,603.44 ± 3,943.28; ± 985.82
GO after MP 428.12 ± 284.85; ± 71.21 5,217.06 ± 3,454.85; ± 863.71
H 236.11 ± 106.68; ± 22.74 2,824.76 ± 1,292.3; ± 275.52
GO before MP vs. GO after MP p = 0.1137 p = 0.1247
GO before MP vs. H p = 0.0167 p = 0.0145
GO after MP vs. H p = 0.0193 p = 0.0166
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important for the induction of remission in patients 
with Graves’ disease [52]. TGFb1’s action can be local 
and systemic. TGFb1, released locally as a result of 
injury or the immune response, has pro-inflammatory 
properties (e.g. it stimulates granulocyte macrophage 
chemotaxis and the release of pro-inflammatory cyto-
kines (TNF, IL-1, IL-6) [5, 24, 25, 53] and profibrogenic 
properties [5, 53, 54]. Among the systemic properties of 
TGFb1, an immunosuppressive effect seems to be the 
most important [5, 24, 25, 53]. Serum concentrations of 
TGFb1 were higher in patients with Graves’ disease 
compared to controls and decreased after treatment for 
hyperthyroidism. Positive correlations were observed 
between thyroid hormones and TGFb1 in patients with 
thyroid dysfunction [55].
Endocrine glands are well vascularised and the 
structure of their vessels (fenestration of epithelium) 
facilitates the exchange of various substances, includ-
ing hormones. The amount of VEGF in the thyroid 
gland is greater in the frequently occurring paren-
chymal and nodular goitres compared to healthy sub-
jects, although a difference between the pathological 
tissues is not stated [25, 33, 56]. Increased mRNA 
and protein expression of VEGF and its receptors 
detected in nodular tissue of uninodular and recur-
rent goitre compared to the corresponding normal 
tissue might be crucial in the proliferation of thyro-
cytes, and therefore may contribute to the develop-
ment of goitre and goitre recurrence [56]. Tissues of 
lymphocytic thyroiditis and differentiated thyroid 
carcinomas have a stronger expression of VEGF than 
healthy gland tissues [25, 57, 58]. Increased VEGF 
expression in malignant thyroid tumours has been 
shown not only compared to healthy tissue, but also 
in relation to benign tumours. TSH stimulation of 
the thyroid cells culture induces their proliferation 
[25, 33]. Stimulation of human thyrocytes by the 
TSH and TRAb leads to an increase in their mRNA 
VEGF expression and in vivo to an increased mRNA 
expression of VEGF, Flt-1 (fms-like tyrosine kinase-1 
receptor; VEGFR1) and KDR (Flk-1; foetal liver ki-
nase-1 receptor; VEGFR2) in the endothelial cells of 
thyroid rats. This points to the participation of VEGF 
in angiogenesis occurring in the thyroid gland, also 
in humans with Graves’ disease [24, 25, 58–60] in 
whom the constant stimulation of thyroid tissue by 
TRAb not only increases the production of thyroid 
hormones, but also enhances angiogenesis, leading 
to an increase in thyroid vascularity which has long 
been widely known [25, 33]. In people with Graves’ 
disease, VEGF mRNA has been found to be localised 
in the hyperplastic thyroid follicular cells, and mRNA 
and protein of Flt-1 in the endothelial cells of all thy-
roid tissues [61]. The highest expression of VEGF and 
its receptors has been found in tissue obtained from 
patients with Graves’ disease [56]. It has been found 
that serum VEGF levels are elevated in patients with 
untreated Graves’ disease and Hashimoto’s disease, 
and correlate positively with the degree of thyroid 
vascularity assessed by colour Doppler ultrasound. 
VEGF C and Flt-4 have also been observed in human 
tissues of goitre and autoimmune thyroiditis [25, 33, 
58]. There was an increase in serum VEGF levels and 
a correlation between the levels and intrathyroidal 
vascular in untreated patients with Graves’ disease 
who had a goitre larger than or equal to 40 cm3 when 
compared to healthy subjects. Serum VEGF levels 
decreased in these patients after treatment [62]. The 
concentrations of serum VEGF were higher in GO 
and Graves’ disease patients than in controls. The 
serum levels of VEGF in patients with active GO were 
higher than those in patients with inactive GO and 
those in Graves’ disease patients. Moreover, serum 
VEGF concentrations were correlated with CAS in 
GO patients [38]. 
Glucocorticoids (e.g. methylprednisolone) modulate 
TGFb1 production [63]. Some researchers, evaluating a 
single measurement of TGFb1 levels in the blood, have 
not demonstrated such a relationship [64]. Glucocor-
ticoids and their receptors interact with signal trans-
duction of TGFb1 at the transcription and translation 
level [65]. TGFb1 increases glucocorticoids binding and 
signalling in macrophages through a Smad2/3-mediated 
process. This may represent a new target for interven-
tion to increase glucocorticoids responsiveness [66]. 
Glucocorticoids, including methylprednisolone in vitro 
potentiated TGFb signalling by the Smad1/5/8 signal-
ling and blunted signalling by the Smad2/3 in primary 
lung fibroblasts, smooth muscle cells, and endothelial 
cells. Dexamethasone acted synergistically with TGFb 
to drive differentiation of primary lung fibroblasts to 
myofibroblasts, revealed by the acquisition of smooth 
muscle actin and smooth muscle myosin, which are 
exclusively Smad1-dependent processes in fibroblasts 
[67]. There are also interesting observations concerning 
the activity of glucocorticoids approved in the treatment 
of autoimmune diseases. For example, in hepatic stellate 
cells after glucocorticoids administration, the TGFb1 
receptor III (TGFbRIII) expression increases in a dose 
dependent manner and time of their administration, 
while TGFb1 receptor I and II (TGFbRI and TGFbRII) 
expression does not change. 
It has been found that the degree of induction of 
TGFbIII expression is dependent on the nature of the 
stimulating hormone - dexamethasone, hydrocortisone, 
aldosterone and their doses. Glucocorticoids, through 
modulation of mRNA TGFbRIII expression, can influ-
ence the final effect of TGFb1. Since TGFb1 and gluco-
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corticoids have immunosuppressive activity, and since 
after glucocorticoids’ administration tissue sensitivity 
to the TGFb1 is increased, it can be assumed that they 
act synergistically. Thus, the beneficial effects of gluco-
corticoids may be the result of a synergistic mechanism 
of intensifying immunosuppression. 
This observation is related to autoimmune hepatitis 
[5, 65], but could it be also connected to glucocorticoid 
therapy of GO? Undoubtedly, in GO, the immunosup-
pressive effects seem to be clinically important, but 
TGFb1 has also a profibrogenic action. Is the simultane-
ous immunosuppressive and profibrogenic response 
induced by glucocorticoid therapy beneficial? Does it 
contribute to the conversion of the active (oedematous-
infiltrative orbitopathy) phase to the non active (fibrosis) 
phase? 
Glucocorticoids (e.g. methylprednisolone) modu-
late also VEGF production. Ye et al. in 2014 showed 
that VEGF levels in corticosteroid-responsive patients 
decreased after corticosteroid treatment, and these 
changes were accompanied by a decrease of CAS. In 
their opinion, the results could reflect the degree of 
ocular inflammatory activity [38].
Conclusions
1. Methylprednisolone therapy increases serum 
TGFb1 daily concentrations (and total daily secre-
tion). The effectiveness of methyloprednisolone 
therapy in patients with active Graves’ orbitopathy 
may be related to its influence on TGFb1 concentra-
tions in blood. The results suggest the existence of a 
new mechanism of glucocorticoids action, consisting 
of an increase in the secretion of TGFb1.
2. The elevated serum VEGF in thyreotoxic patients 
with active Graves’ orbitopathy may reflect long-
standing autoimmune processes in orbital and 
thyroid tissues and intensified angiogenesis in the 
thyroid gland. 
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